Minerva Neurosciences | NERV - Ebit


Minerva Neurosciences reported $-4.37M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Adma Biologics USD 62.75M 13.56M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.06B 530M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024